Tucotuzumab celmoleukin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tucotuzumab celmoleukin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetEpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 339986-90-2 checkY
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC7812H12124N2044O2408S60
Molar mass175130.42 g·mol−1
  (verify)

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]

This drug was developed by EMD Pharmaceuticals.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
  2. ^ Clinical trial number NCT00016237 at ClinicalTrials.gov
  3. ^ "Definition of tucotuzumab celmoleukin". National Cancer Institute.